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ABSTRACT
Objective: To compare the safety and efficacy of
the dipeptidylpeptidase-4 (DPP-4) inhibitors in
patients with type 2 diabetes and inadequate
glycemic control.
Design: Systematic review of randomized
controlled trials (RCTs), health economic
evaluation studies, systematic reviews, and
meta-analyses, followed by primary Bayesian
mixed treatment comparison meta-analyses
(MTCs), and secondary frequentist direct-
comparison meta-analyses using a random-
effects model. Outcomes were reported as
weighted mean change from baseline, or odds
ratio (OR) with 95% credible interval.
Data sources: MEDLINE, MEDLINE In-Process,
EMBASE, and BIOSIS via Dialog ProQuest;
Cochrane Central Register of Controlled Trials
and Cochrane Database of Systematic Reviews
via EBSCO; four diabetes and two technical
congress abstracts; and health technology
assessment organization websites.
Eligibility criteria: Patients with type 2 diabetes
and inadequate glycemic control receiving any
pharmacological anti-diabetic treatment.
Data extraction and analysis: Title/abstracts
were reviewed for eligibility, followed by full-
text review of publications remaining after first
pass. A three-person team filtered articles and
an independent reviewer checked a random
selection (10%) of filtered articles. Data
extraction and quality assessment of studies
were also independently reviewed. Five DPP-4
inhibitors (alogliptin, linagliptin, saxagliptin,
sitagliptin, and vildagliptin) were compared via
meta-analysis (where data were available) as
monotherapy, dual therapy (plus metformin,
sulfonylurea, pioglitazone, or insulin), and
triple therapy (plus metformin/sulfonylurea).
Results: The review identified 6,601 articles;
163 met inclusion criteria and 85 publications
from 83 RCTs contained sufficient or
appropriate data for analysis. MTCs
demonstrated no differences between DPP-4
inhibitors in mean change from baseline in
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glycosylated hemoglobin (HbA1c) or body
weight, or the proportions of patients
achieving HbA1c \7% or experiencing a
hypoglycemic event, apart from in patients on
alogliptin plus metformin, who achieved HbA1c
\7% more frequently than those treated with
saxagliptin plus metformin [OR 6.41 (95% CI
3.15–11.98) versus 2.17 (95% CI 1.56–2.95)].
Conclusions: This systematic review and MTC
showed similar efficacy and safety for DPP-4
inhibitors as treatment for type 2 diabetes,
either as monotherapy or combination therapy.
Keywords: Alogliptin; DPP-4 inhibitor;
Glycosylated hemoglobin; Linagliptin; Mixed
treatment comparison; Saxagliptin; Sitagliptin;
Type 2 diabetes mellitus; Vildagliptin
INTRODUCTION
Dipeptidylpeptidase-4 (DPP-4) inhibitors have a
mechanism of action that is distinct from other
oral glucose-lowering agents [1]. The DPP-4
inhibitor class of oral anti-diabetic agents
selectively inhibits the DPP-4 enzyme that
rapidly degrades two major incretin hormones,
glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide [2].
Scheen [2] reviewed DPP-4 inhibitors in 2011,
analyzing the similarities and differences among
members of the DPP-4 inhibitor class of oral anti-
diabetic agents, including their efficacy and safety
profiles as monotherapy or in combination with
metformin, a sulfonylurea (SU) and/or a
thiazolidinedione, and insulin. The review
demonstrated that, although DDP-4 inhibitors
produce a similar reduction in glycosylated
hemoglobin (HbA1c) levels compared with other
existing classes of oral glucose-lowering agents,
DPP-4 inhibitors offer several clinical advantages
[3]. These include negligible risk of
hypoglycemia, much lower than that observed
with SUs, and weight neutrality, compared with
the weight gain that is generally associated with
SUs and thiazolidinediones [2].
Previous indirect comparisons of the DPP-4
inhibitors in several published meta-analyses
[4–8] have reported little or no difference
between them with regard to efficacy, both as
monotherapy and in combination with other
anti-diabetic drugs, and the overall safety
profile [2]. However, there are several
important differences between the DPP-4
inhibitors with regard to their absorption,
distribution, metabolism, and elimination, as
well as potency and duration of action [2].
These differences may, potentially, be clinically
relevant, particularly in patients with renal or
hepatic impairment, and in patients receiving
combination therapy, especially those with
cardiovascular disease taking multiple drugs [2,
9]. However, there is a lack of head-to-head
clinical trials comparing DPP-4 inhibitors: a
single clinical trial was identified in the Scheen
review [2]. This 18-week trial compared the
efficacy of saxagliptin 5 mg and sitagliptin
100 mg in combination with metformin in
patients with type 2 diabetes inadequately
controlled with metformin alone [10]. The
between-group adjusted mean change from
baseline in HbA1c demonstrated no difference
between saxagliptin and sitagliptin.
Esposito et al. [5] conducted a systematic
review and meta-analysis of indirect comparisons
of the DPP-4 inhibitors vildagliptin, sitagliptin,
saxagliptin, and alogliptin in 2011. The primary
outcome of the analysis was the proportion of
patients achieving an HbA1c level\7%, with the
absolute change from baseline in HbA1c,
proportion of patients with hypoglycemic
events, and change from baseline in body
weight as secondary outcomes. The systematic
review of published literature identified no
randomized controlled trials (RCTs) with the
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DPP-4 inhibitor linagliptin and was limited to
trialspublished up until September 2010. Separate
meta-analyses were conducted for each DPP-4
inhibitor compared with placebo and other anti-
diabetic agents (including metformin, SUs,
pioglitazone, and rosiglitazone) for each of the
outcomes.
We have conducted a similar review of DPP-4
inhibitors; as monotherapy compared with
placebo, and as dual or triple therapy (where
data were available) compared with metformin,
SUs, metformin plus SU, pioglitazone, and
insulin. Included studies were identified for all
pharmacologic therapies for type 2 diabetes.
Following this wider review, we extracted data
from RCTs in patients treated with a DPP-4
inhibitor and conducted mixed treatment
comparison meta-analyses (MTCs) to
demonstrate the relative treatment effects of
each DPP-4 inhibitor compared with a common
comparator, assessing the same four outcomes
as reported by Esposito et al. [5].
The aim of the MTCs was to test the
hypothesis of no difference between the DPP-4
inhibitors with regard to glycemic control
[mean HbA1c change from baseline, proportion
of patients achieving target HbA1c (\7%)],
number of patients with hypoglycemic events,
and mean change from baseline in body weight.
METHODS
The analysis in this article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
Systematic Literature Search
We conducted a systematic review of published
literature to assess the comparative efficacy and
safety of DPP-4 inhibitors compared to other
oral and injectable anti-diabetic pharmacologic
interventions, including insulin, in the
treatment of patients with type 2 diabetes who
were receiving monotherapy, dual, or triple
therapy. The research question and eligibility
criteria for this systematic review conformed to
the following PICOS description [11]; studies
meeting these criteria were considered for
inclusion:
• Population: patients of any age or sex with
type 2 diabetes and insufficient glycemic
control (including first-, second-, and third-
line treatment regimens).
• Intervention: any DPP-4 inhibitor (alogliptin,
linagliptin, saxagliptin, sitagliptin, and
vildagliptin), GLP-1 or sodium-glucose co-
transporter 2 inhibitors, or pioglitazone used
in the treatment of type 2 diabetes (as
monotherapy, dual or triple therapy).
• Comparator: any pharmacologic anti-
diabetic treatment, placebo, or standard of
care for diabetes.
• Outcome(s): HbA1c (mean change from
baseline and proportion of patients
achieving HbA1c target), fasting plasma
glucose (FPG), low-density lipoprotein
cholesterol, high-density lipoprotein
cholesterol, triglycerides, body weight, and
hypoglycemia and serious adverse events.
• Study type(s): blinded and open-label RCTs,
health economic evaluation studies,
systematic reviews, and meta-analyses.
Observational studies and retrospective
analyses were not included.
Please note that this article focuses on
analyses of DPP-4 inhibitors for the following
outcomes: mean change in HbA1c from
baseline, proportion of patients achieving
HbA1c \7%, mean change from baseline in
body weight, and number of patients
experiencing a hypoglycemic event.
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Published RCTs, health economic evaluation
studies, systematic reviews, and meta-analyses,
were identified from a systematic search of
electronic databases with no publication date
or language restrictions applied. Databases were
searched via Dialog ProQuest [12] [MEDLINE
and MEDLINE In-Process; EMBASE and BIOSIS
for conference abstracts (limited to the previous
3 years)] and EBSCO [13] (Cochrane Central
Register of Controlled Trials, Cochrane
Database of Systematic Reviews), NHS
Economic Evaluation Database [14], and Heath
Economic Evaluations Databases [15] for
systematic reviews of health economic
outcomes. All electronic databases were
searched on November 30, 2012. Reference
lists of selected systematic reviews and meta-
analyses meeting the inclusion criteria were
reviewed to identify further studies, including
unpublished studies. ‘Grey literature’ searches
were also conducted of relevant congresses
(American Diabetes Association [16], European
Association for the Study of Diabetes [17],
International Diabetes Federation [18],
Canadian Diabetes Association [19], Health
Technology Assessment (HTA) International
[20] and International Society for
Pharmacoeconomics and Outcomes Research
[21]), limited to the previous 3 years. Other
appropriate sources searched included the
ClinicalTrials.gov website of the US National
Institutes of Health [22], and HTA databases
including those from the International Network
of Agencies for Health Technology Assessment
[23], National Institute for Health and Care
Excellence (NICE) [24], National Institute for
Health Research [25], and Canadian Agency for
Drugs and Technologies in Health [26]. A
structured search string was employed,
including terms for type 2/non-insulin
dependent diabetes mellitus and drug therapy.
Specific filters for retrieving RCTs conducted in
humans, meta-analyses, systematic reviews, and
health economic evaluation studies were
incorporated into the search string. The full
search string is presented in Appendix 1
(Electronic Supplementary Material).
Any abstracts associated with full-text
articles were identified. If more than one
article presented data from the same study
population, only data from the most recent
full-text publication were included. If a
conference abstract superseded a full-text
publication, data from outcomes presented in
the conference abstract that were not included
in the full-text publication were utilized.
Study Selection
Identified articles were screened to ensure they
met predetermined inclusion criteria. Each
reviewer was provided with a checklist based on
the inclusion/exclusion criteria specified in the
systematic review protocol (Commercial in
confidence), and a structured Microsoft Excel
(Microsoft Corp, Redmond, WA, USA)
spreadsheet was used to ensure uniformity of
appraisal for each study. Initially, titles or
abstracts (or both) of all identified citations were
reviewed according to a first-pass checklist. Full-
text publications of the citations remaining after
the first pass were then reviewed according to a
second-pass checklist. A three-person team
reviewed the articles at first and second pass, and
an independent reviewer checked a random
selection (10%) of filtered articles for consistency.
A positive exclusion method was used,
whereby studies for which there were
insufficient information for exclusion
remained in the review until a stage where it
could be proven that they did not meet the
inclusion criteria.
Although the systematic review included all
pharmacologic treatments for type 2 diabetes,
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in this paper we report only the analyses of
DPP-4 inhibitors.
Data Extraction
The Microsoft Excel spreadsheet designed to
ensure uniformity of appraisal was subsequently
used to capture all relevant data for included
studies. All data extracted for meta-analysis
were also independently reviewed and
reviewers came to a consensus regarding the
final data recorded for each study. Data input
sheets for the meta-analyses, including data
imputations, were also checked for accuracy by
a second reviewer prior to conducting the
analyses. Extracted data consisted of study
characteristics [such as study design, duration,
primary and secondary endpoints, study
inclusion and exclusion criteria, treatment and
dose (including schedule and strategy), and
patient baseline characteristics (age,
comorbidities, renal impairment,
cardiovascular risk, concomitant medications,
and disease duration)]. Extracted data were
grouped such that information for different
treatment regimens could be easily identified.
Assessment of Data for Meta-analysis
Studies were assessed to establish whether
sufficient and appropriate data were reported
for the relevant outcomes. Studies were
excluded based on the following criteria:
article reported extension phase of an RCT
already included; lack of common comparator
(i.e., no connection within treatment network);
inappropriate patient population (e.g., patients
with adequate glycemic control, mixed
population with type 1 diabetes); insufficient
data for standard error imputation (i.e., patient
numbers not given); cross-over study; and
duplicate data.
Quality Assessment
Studies from which data were extracted were
assessed for robustness as sources of
information for inclusion in subsequent
statistical analyses. Quality assessment was
conducted according to the methods and
assessment instruments recommended by the
HTA authorities in France, Germany, Italy,
Spain, UK, USA, and Canada. Hierarchical
assessment of the risk of bias was conducted as
recommended by the Institute for Quality and
Efficiency in Health Care (Germany) in their
guidelines on methods for conducting
systematic reviews [27], checklist criteria
recommended by l’Agence nationale
d’accre´ditation et d’e´valuation en sante´
(France) in their guide to the literature and
grading of recommendations [28], and quality-
assessment criteria recommended by NICE (UK)
in their single technology appraisal template
[29]. Study quality was also independently
reviewed. Clinical trials were also evaluated to
assess whether they had been reported
according to the Consolidated Standards of
Reporting Trials [30] checklist. Study quality
was not used as an inclusion/exclusion criterion
or to weight individual studies in the meta-
analyses.
Data Imputation
Where studies did not explicitly report standard
errors, these were derived from available
published information. If possible, standard
errors were obtained from confidence intervals
(CIs) and standard deviations (SDs); if these data
were unavailable, they were derived from the
p value referring to the change from baseline. If
none of the above was available, standard errors
were imputed using data from other well-
reported studies, using methods outlined by
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the Cochrane Collaboration [31]. Alternatively,
as a final option, if there was no other well-
reported study, p values for the difference
between treatments were used and the pooled
SD applied to both arms. Mean changes from
baseline values were derived by subtracting
before and after values, if not explicitly stated.
Quantitative Analysis
Direct evidence was assessed by conducting
random-effects meta-analyses in a frequentist
setting in Stata (Version 12; StataCorp, College
Station, TX, USA) for each DPP-4 inhibitor (as
monotherapy, dual and triple therapy) against
common comparator arms. In studies reporting
results for multiple DPP-4 inhibitor doses, only
data related to the licensed dose were included
in the analysis. Data were presented as the effect
estimate and 95% CI. Heterogeneity was
assessed using the I2 statistic, i.e., the
percentage of the variability in effect estimates
due to heterogeneity rather than sampling
error. Interpretation of the I2 statistic was in
accordance with the Cochrane Collaboration
recommendations [31]. For direct comparisons
that reported I2 values [30%, sensitivity
analyses were considered and were conducted
where outliers were identified to assess
robustness of the pooled effect estimate.
Mixed treatment comparison meta-analyses
were also performed to demonstrate the relative
treatment effects of each DPP-4 inhibitor (as
monotherapy, dual or triple therapy) using a
Bayesian framework and Markov chain Monte
Carlo methods, which were fitted using the
Bayesian software in WinBUGS (Medical
Research Council Biostatistics Unit,
Cambridge, UK) [32]. This allowed for direct
evidence (within-trial comparisons between
treatments) and indirect evidence (treatments
within different trials with a common
comparator) to be considered simultaneously.
Typically, models consisted of 100,000
iterations with a 50% burn-in sample.
Standard diagnostics tools were used to assess
convergence to the stationary distribution. This
included observing random walk plots for each
node and assessment of the Gelman–Rubin
diagnostic statistic. The rejection sampler
followed the standard hierarchy of sampling
methods in the WinBUGS program [32]. Initial
values were generated randomly for different
chains to assess the robustness of different
starting values. Random-effects models were
utilized to account for heterogeneity from
varying study populations.
Mean changes from baseline in HbA1c and
body weight outcomes are both continuous
measures. These were estimated using a vague
prior normal distribution, allowing the data to
have maximum leverage over the iterative
process. Data were presented as a weighted
mean difference between treatments.
Proportions of patients with HbA1c \7% and
hypoglycemic-event outcome measures are
binomial (the outcome is either achieved or
not). For this type of data, the probability of the
outcome was modeled using a binomial
distribution. Each pair of treatments was
compared by estimating the odds ratio (OR) of
the outcome. Each study within each random-
effects meta-analysis had a weight based on the
within-study variation. It was assumed that
each log OR had been sampled from a normal
distribution and that the treatment effects were
wholly exchangeable within studies.
Data for all DPP-4 inhibitor and comparator
doses were included in the analyses for studies
that reported multiple doses. All data were
presented as an effect estimate and 95%
credible interval, with 95% credible intervals
6 Diabetes Ther (2014) 5:1–41
that did not include zero deemed statistically
significant. Overlapping 95% credible intervals
were considered as evidence of no difference
between treatments.
Mixed treatment comparison meta-analyses
were conducted for absolute and relative (vs.
comparator) treatment effects. Absolute
treatment-effect calculations required an
estimate for the efficacy of the comparator
arm to be entered into the MTC. Direct-
comparison meta-analyses were conducted to
obtain more accurate estimates of the
comparator treatment effects (see Table 1).
Consistency Between Direct and Indirect
Data
The consistency of direct and indirect
comparisons was assessed for nodes comparing
DPP-4 inhibitors directly. A single study
reported direct comparison data of two DPP-4
inhibitors (sitagliptin and saxagliptin) plus
metformin. Thus, consistency tests assessing
the relationship between sitagliptin plus
metformin and saxagliptin plus metformin for
mean change from baseline HbA1c and
proportion of patients achieving HbA1c \7%
were conducted using Bucher’s extended
method for multiple loops [33]. Bucher’s
method for multiple loops combines direct
and indirect evidence for multiple pathways
and these multiple loops construct a v2 test
statistic. The p value attained from the
calculated v2 statistic gives the probability of
observing a test statistic at least as extreme as
the calculated value, given the null hypothesis
of consistency between direct and indirect
evidence is true. If this p value is \0.01,
typically, this hypothesis is rejected [33].
RESULTS
Data Selection
Figure 1 shows the selection process for articles
in the systematic review and meta-analyses.
Seventy-eight studies were excluded since they
were deemed to contain insufficient or
inappropriate data based upon criteria
described in the ‘‘Methods’’ [see Appendix 2 for
a listing (Electronic Supplementary Material)].
Sixty non-English articles proceeded to
second pass, of which only two reported
results of an RCT with a DPP-4 inhibitor. Both
of these articles included the DPP-4 inhibitor,
anagliptin, which is only licensed in Japan and
was only reported in these two articles. Thus, it
was not eligible for inclusion in the mixed
treatment comparison network and was
excluded from the analysis.
Characteristics of Included Studies
Appendix 3 (Electronic Supplementary Material)
provides details of the 83 RCTs included. Of
these, 82 compared DPP-4 inhibitor treatment
regimens with placebo, metformin (± SU,
pioglitazone or insulin), SU, pioglitazone, or
insulin, while one directly compared sitagliptin
plus metformin with saxagliptin plus
Table 1 Comparator meta-analysis estimates of treatment








Metformin plus sulfonylurea -0.033 (0.038)
Pioglitazone -0.657 (0.032)
Insulin -0.155 (0.069)
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metformin [10]. All RCTs were included in at
least one of the analyses; each RCT could be
used in multiple sets of analyses.
Quality assessment of studies for which data
were extracted (Appendix 4, Electronic
Supplementary Material) indicated two studies
that represented high-quality or robust sources
of information [34, 35], as they were deemed to
be of high quality by all quality-assessment
criteria. However, it is worth noting that the
majority of studies from which data were
extracted and subsequently included in the
statistical analyses were deemed to have three
or fewer ‘unclear’ ratings, which could
potentially indicate that the level of reporting
was not sufficient to determine an accurate
assessment of robustness. Ten studies were
assessed as representing low-quality or non-
robust sources of information [36–46]; however,
all were deemed to have two or more ‘unclear’
ratings and only a single study [40] was
included in the subsequent statistical analysis.
The majority of RCTs were double blind.
However, five articles reported data from open-
label RCTs [36, 47–50]. Trial durations varied
widely—from 4 weeks to 104 weeks. Two studies
included an initial 12-week randomization
stage followed by a 40-week extension [34, 51].
Inclusion criteria for the majority of trials
included baseline HbA1c levels of 6.0–11.0%.
However, a number of trials included patients
with higher baseline HbA1c levels, which might
Fig. 1 Number of articles proceeding at each stage of the
systematic review. Articles excluded for more than one
reason. Number of RCTs does not add up to 83 as each
RCT could be used in multiple sets of analyses. DPP-4
dipeptidylpeptidase-4 inhibitor, RCT randomized con-
trolled trial, SU sulfonylurea
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have resulted in greater HbA1c reductions
during the study. Indeed, baseline HbA1c levels
reported by Pfu¨tzner et al. [52] were 8.0–12.0%,
Derosa et al. [53][8.0%, Pe´rez-Monteverde et al.
[54] 7.5–12.0%, Wainstein et al. [55] 7.5–12.0%,
Jadzinsky et al. [56] 8.0–12.0%, and Yoon et al.
[57] 8.0–12.0%. The majority of trials included
patients with body mass index (BMI) B40 kg/
m2. However, 7 trials included patients with a
lower maximum baseline BMI [53, 58–63] and
18 trials included patients with a higher
maximum baseline BMI [35, 47, 48, 64–78].
Increased BMI outside the normal range (BMI
18.5–25.0 kg/m2; healthy weight), as classified
by the World Health Organization [79], is
associated with type 2 diabetes and comorbid
conditions including hypertension and
dyslipidemia. The mean age of patients was
similar between studies, apart from four studies
[63, 73, 80, 81], in which the mean age of
patients was C65 years. Elderly patients may
have many comorbid conditions or functional
disabilities and may take multiple additional
medications (polypharmacy).
In the majority of trials, the primary outcome
was mean change in HbA1c from baseline to
endpoint. However, eight trials reported co-
primary outcomes to HbA1c change from
baseline [54, 59, 62, 64, 82–85], such as change
from baseline in FPG, 2-hour postprandial
glucose, BMI, body weight, fasting lipids,
fasting plasma insulin, fasting insulin, fasting
C-peptide, vital signs, and number/proportion of
patients with adverse events, homeostatic model
assessment-insulin resistance (b-cell function),
and proportion of patients achieving HbA1c\7%.
In five trials, HbA1c change from baseline was not
the primary outcome [36, 53, 68, 86, 87]. Instead,
the primary outcome was another blood glucose
measure (e.g., postprandial blood glucose and
change from baseline in 24-h weighted mean
glucose), postprandial GLP-1 response, change in
insulin secretion at endpoint, or change from
baseline in postprandial incremental analytical
ultracentrifugation for total plasma triglycerides.
Direct-comparison Meta-analyses
and Mixed Treatment Comparisons
The quantitative analyses investigated the difference
between treatments in the mean change from
baseline HbA1c, OR for proportion of patients
achieving HbA1c target (\7%), mean change from
baseline in body weight, and OR for the number of
patients reporting a hypoglycemic event.
First, the direct evidence was assessed by
conducting random-effects meta-analyses for
each DPP-4 inhibitor (as monotherapy, dual or
triple therapy) against placebo, metformin, SU,
metformin plus SU, pioglitazone, metformin
plus pioglitazone, insulin, and metformin plus
insulin. MTCs were then developed from the
network of DPP-4 inhibitor trials identified in
the systematic review. Eligible network
comparisons for HbA1c mean change from
baseline for DPP-4 inhibitors (as monotherapy,
dual or triple therapy) are presented in Fig. 2. As
an example, we have presented the networks for
HbA1c mean change from baseline in this paper
as these represent the most complex treatment
networks and include the majority of trials
(networks for the proportion of patients
achieving HbA1c level \7%, mean change from
baseline in body weight, and proportion of
patients experiencing a hypoglycemic event are
available on request).
Individual study data for each of the four
outcomes analyzed in the meta-analyses are
summarized in Table 2 [10, 34–36, 40, 47–127].
Direct-comparison meta-analysis results are
presented in Tables 3 and 4 for continuous and
binominal outcomes, respectively. Results of the
relative and absolute treatment effects in the MTCs
are presented in Tables 5 and 6, respectively.
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DPP-4 Monotherapy
In the direct-comparison analysis, all DPP-4
inhibitors were significantly more effective than
placebo in achieving a greater mean reduction
from baseline in HbA1c and a greater proportion
of patients achieved HbA1c levels\7% (Tables 3,
4). However, the I2 statistic for linagliptin
studies in the HbA1c change from baseline
analysis (33.0%) may represent moderate
heterogeneity, and the I2 statistic for
sitagliptin studies in the HbA1c \7% analysis
(63.7%) may represent substantial heterogeneity,
in the effect estimates.
The relative treatment effects in the MTC
analysis showed that DPP-4 inhibitors as
monotherapy were significantly more effective
than placebo at reducing mean HbA1c from
baseline (Table 5). Patients treated with any of
the DPP-4 inhibitors, except for saxagliptin,
were statistically significantly more likely to
Fig. 2 Networks of eligible comparisons for HbA1c mean
change from baseline for a DPP-4 monotherapy, b DPP-4
plus metformin, c DPP-4 plus SU, d DPP-4 plus
metformin plus SU, e DPP-4 plus pioglitazone, and
f DPP-4 plus insulin. The width of the lines is proportional
to the number of trials comparing each pair of treatments,
and the size of each node is proportional to the number of
trials for each treatment. DPP-4 dipeptidylpeptidase-4
inhibitor, HbA1c glycosylated hemoglobin, SU sulfonylurea
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achieve HbA1c \7% than those treated with
placebo (Table 5). Treatment with either
sitagliptin or vildagliptin resulted in a
statistically significant increase in mean (95%
CI) body weight relative to placebo of 0.70 kg
(0.33–1.08 kg) and 0.83 kg (0.39–1.27 kg),
respectively. There was no significant
difference in mean change from baseline in
body weight for alogliptin or linagliptin versus
placebo. Only linagliptin resulted in statistically
significant lower odds of patients having a
hypoglycemic event compared with placebo
[OR 0.18 (95% CI 0.0074–0.77)].
Absolute mean changes in HbA1c from
baseline to study endpoint were all reductions
(i.e., improvements; Table 6); however, all
reductions were non-significant. There was no
significant difference between treatments in
absolute mean body weight change from
baseline for any DPP-4 inhibitor.
DPP-4 Plus Metformin
In the direct-comparison meta-analysis, all DPP-4
inhibitors as dual therapy with metformin
were significantly more effective in achieving a
greater mean reduction from baseline in HbA1c
and achieving a greater proportion of patients
with HbA1c levels \7% compared with
metformin alone (Tables 3, 4). However, I2
statistics [30% may represent heterogeneity in
the treatment effect of alogliptin (I2 79.8%),
saxagliptin (I2 60.5%), and vildagliptin (I2
94.9%) for the HbA1c mean change from
baseline outcome, and of alogliptin (I2 76.5%),
saxagliptin (I2 53.7%), and sitagliptin (I2 80.0%)
for the proportion of patients achieving HbA1c
\7%.
A single head-to-head trial provided data
directly comparing two DPP-4 inhibitors:
sitagliptin plus metformin versus saxagliptin
plus metformin [10]. The HbA1c mean change
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saxagliptin or sitagliptin added to stable
metformin therapy was shown to be 0.09%
(95% CI -0.01 to 0.20%), which is below the
predefined criterion (\0.3%) for non-inferiority.
The relative MTCs showed that all DPP-4
inhibitors plus metformin were significantly
more effective than metformin alone in
reducing mean HbA1c from baseline and
achieving a higher proportion of patients with
HbA1c \7% (Table 5). Patients treated with
alogliptin were statistically significantly more
likely to achieve HbA1c \7% than patients
treated with saxagliptin; however, it should be
noted that the 95% credible interval for
alogliptin plus metformin was very wide [OR
6.41 (3.15–11.98)]. The direct and indirect
treatment effects for HbA1c change from
baseline for saxagliptin plus metformin and
sitagliptin plus metformin were shown to be
consistent, as assessed by Bucher’s method [33],
for HbA1c mean change from baseline
(p = 0.16), but inconsistent for the proportion
of patients achieving HbA1c \7% (p\0.05).
There were no significant differences in mean
change in body weight reported between DPP-4
plus metformin and metformin alone. No body
weight data were available for saxagliptin.
Absolute mean changes from baseline to study
endpoint in mean HbA1c levels were all
reductions (i.e., improvements); however,
none was statistically significant. Mean
changes from baseline to study endpoint in
body weight were also non-significant (Table 6).
DPP-4 Plus Sulfonylurea
In the direct-comparison analysis, linagliptin,
saxagliptin, sitagliptin, and vildagliptin as dual
therapy with SUs were significantly more
effective in achieving a greater reduction in
mean HbA1c than SU alone (Tables 3, 4);
however, data for linagliptin and saxagliptin
were based on only one study and are
inconsistent with the vildagliptin studies
(HbA1c mean change from baseline, mean
body weight change from baseline, and
proportion of patients achieving HbA1c \7%
(I2 59.4, 66.5, and 92.6%, respectively).
In the MTCs, all DPP-4 inhibitors as dual
therapy with SU were significantly more
effective relative to SU alone in reducing
HbA1c levels (Table 5). No data were available
for alogliptin plus SU for HbA1c mean change
from baseline. Patients receiving dual therapy
were more likely to achieve HbA1c \7% than
those treated with SU alone; however, only the
vildagliptin plus SU comparison reached
statistical significance, OR 5.81 (95% CI
1.35–15.11).
There was no significant difference between
treatments in absolute mean change from
baseline to endpoint in HbA1c or body weight
for any comparison (Table 6).
DPP-4 Plus Metformin Plus Sulfonylurea
Direct-comparison data were only available for
linagliptin, sitagliptin, and vildagliptin, with
one study included for each; I2 analysis was,
therefore, not possible. Mean changes from
baseline in HbA1c for sitagliptin, linagliptin,
and vildagliptin were -0.890% (95% CI -2.41
to 0.63%), -0.20% (95% CI -0.73 to -0.51) and
-0.760% (95% CI -1.01 to -0.51%),
respectively, and mean changes in body
weight for linagliptin and sitagliptin were
0.330 kg (95% CI -0.3 to 0.69 kg) and
0.700 kg (95% CI -0.22 to 1.62 kg),
respectively (Tables 3, 4). The proportion of
patients experiencing hypoglycemic events
was reported for linagliptin [OR 1.689 (95% CI
1.16–2.47)], sitagliptin [OR 8.699 (95% CI
1.07–70.76)], and vildagliptin [OR 2.791 (95%
CI 0.73–10.72)].
In the MTC, triple therapy with either
sitagliptin, linagliptin or vildagliptin, in
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combination with metformin and SU, resulted
in a non-significant relative mean reduction in
HbA1c compared with metformin plus SU. There
were insufficient studies reporting the
proportion of patients achieving HbA1c \7% to
evaluate this outcome. Neither linagliptin nor
sitagliptin as triple therapy, in combination
with metformin and SU, resulted in a significant
mean change from baseline in body weight
(Table 5). Change from baseline in body
weight was not reported for vildagliptin triple
therapy.
There was no significant difference between
sitagliptin, linagliptin, and vildagliptin in
absolute mean change from baseline to
endpoint in HbA1c. Neither linagliptin nor
sitagliptin treatment combination resulted in
significant changes in body weight from
baseline (Table 6).
DPP-4 Plus Pioglitazone
In the direct-comparison analysis, all DPP-4
inhibitors (except saxagliptin, for which no data
were available) plus pioglitazone were
significantly more effective than pioglitazone
alone in achieving a greater reduction in HbA1c
from baseline and achieving a greater
proportion of patients with HbA1c levels \7%
(Tables 3, 4), although the I2 statistics for
alogliptin (86.6% and 54.6%, respectively)
may represent substantial heterogeneity.
In the MTC, all DPP-4 inhibitors as dual
therapy with pioglitazone were significantly
more effective relative to pioglitazone alone in
reducing mean HbA1c levels from baseline. All
DPP-4 inhibitors (except linagliptin) achieved a
statistically significant greater proportion of
patients with HbA1c level \7% (Table 5). Only
linagliptin plus pioglitazone resulted in a
statistically significant increase in body weight
compared with pioglitazone alone (1.20 kg;
95% CI 0.06–2.34 kg).
There was no statistically significant
difference between treatments in absolute
mean change from baseline to endpoint in
HbA1c or body weight for any comparison
(Table 6).
DPP-4 Plus Metformin Plus Pioglitazone
As only a single study reported data for a DPP-4
inhibitor (alogliptin) as triple therapy with
metformin plus pioglitazone [65], meta-
analyses were not possible. The addition of
alogliptin and pioglitazone to metformin
therapy was shown to result in statistically
significant reductions in mean HbA1c from
baseline (-1.4% ± SD 0.05%; p\0.001). When
added to metformin, the triple combination
therapy of alogliptin (pooled dose; 12.5 or
25 mg) and pioglitazone (pooled dose; 15, 30,
or 45 mg) was shown to be statistically
significantly more effective than either drug in
dual therapy with metformin (p B 0.001).
Compared with pioglitazone plus metformin
dual therapy, triple combination therapy with
alogliptin was not associated with a statistically
significant gain in body weight or increased
incidence of hypoglycemic events.
DPP-4 Plus Insulin
Data were only available for sitagliptin and
vildagliptin. In the direct-comparison analysis,
neither sitagliptin nor vildagliptin was
statistically significantly more effective than
insulin alone in achieving a greater reduction
in mean HbA1c from baseline or achieving a
greater proportion of patients with HbA1c levels
\7% (Tables 3, 4).
Diabetes Ther (2014) 5:1–41 29
There was no statistically significant
difference between sitagliptin or vildagliptin in
the MTC of both DPP-4 inhibitors plus insulin
in the relative mean change from baseline to
endpoint in HbA1c. Neither of the DPP-4
inhibitors plus insulin effected a significant
difference in change in mean body weight
from baseline compared with insulin alone,
nor statistically significant ORs of patients
experiencing a hypoglycemic event (Table 5).
There was no statistically significant
difference between sitagliptin and vildagliptin
in absolute mean change from baseline to
endpoint in HbA1c or body weight (Table 6).
DPP-4 Plus Metformin Plus Insulin
Only one study reported data for a DPP-4
inhibitor (sitagliptin) as triple therapy with
metformin and insulin [36]; meta-analyses
were, therefore, not possible. The addition of
sitagliptin to insulin plus metformin resulted in
a statistically significantly greater mean
reduction in HbA1c from baseline (-1.49%;
p\0.05) and a greater proportion of patients
achieving HbA1c \7% (88%; p\0.05) versus
metformin plus insulin. A statistically non-
significant increase in body weight was
observed (0.1 ± SD 1.6 kg) with triple
combination therapy of sitagliptin plus insulin
and metformin versus metformin plus insulin.
Sensitivity Analyses
Sensitivity analyses were conducted to assess
the robustness of the conclusions drawn from
the base-case estimates. As the Cochrane
Collaboration considers I2[30% to represent
moderate heterogeneity in the effect estimate,
analyses breaching this threshold were
examined. Appendix 5 (Electronic
Supplementary Material) shows direct-
comparison meta-analyses with I2[30%.
Study references highlighted in bold were
identified as outliers in the forest plots (data
not shown) of these analyses, suggesting that
these studies may be a major cause of
inconsistency in the effect estimate. Two
studies were identified as outliers for HbA1c
mean change from baseline [88, 89] and two
were identified for proportion of patients
achieving HbA1c \7% [89, 90].
Sensitivity analyses were performed by
investigating the effect of removing these
outliers from the respective direct-comparison
analyses. No further action was possible for
analyses in which there were only two studies,
as it was not possible to identify which study
was likely to represent a ‘true’ estimate of the
effect. Heterogeneity in the HbA1c mean change
from baseline analysis for linagliptin versus
placebo was not examined as the I2 statistic
was borderline at 33% and there was no obvious
outlier in the forest plot.
Table 7 summarizes the new I2 values from
studies that remained in the direct-comparison
meta-analysis for each outcome when outlying
studies had been removed. These studies all
compared a DPP-4 inhibitor plus metformin
versus metformin alone and removing them
reduced inconsistency in the treatment effect.
The I2 values for mean HbA1c change from
baseline in the saxagliptin plus metformin
versus metformin and sitagliptin plus
metformin versus metformin comparisons
decreased by 60.5% and 30.3%, respectively.
For the HbA1c\7% outcome, the I
2 value for the
sitagliptin plus metformin versus metformin
comparison decreased by 80% when DeFronzo
et al. [89] was removed. Raz et al. [90] was also
highlighted as a possible outlier responsible for
the inflated I2 value for the direct-comparison
meta-analysis of sitagliptin plus metformin
versus metformin. However, when this study
was removed, the I2 value increased by 9.2% so
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the study was re-introduced into the model for
the MTC.
Table 7 reports how direct-comparison meta-
analysis effect sizes changed insensitivity analyses
in which the DeFronzo et al. [89] and Bosi et al.
[88] studies were removed from the analysis.
Although the removal of studies that were
highlighted as outliers in direct meta-analyses
reduced I2 values, average effect sizes and
direction of effect remained largely
unchanged. CIs narrowed, indicating greater
consistency in the effect estimate.
Following this, relative MTCs were re-run for
both the HbA1c change from baseline and HbA1c
\7% networks (Table 8). The removal of
DeFronzo et al. [89] and Bosi et al. [88]
resulted in a small reduction in the effect
estimate for weighted mean change in HbA1c
from baseline with vildagliptin plus metformin;
however, this change did not affect the non-
inferiority conclusion for all DPP-4 plus
metformin therapies. Similarly, there were also
small reductions for linagliptin plus metformin
and sitagliptin plus metformin for the OR of
patients achieving HbA1c\7%. Similar to HbA1c
mean change from baseline, effect estimates for
proportion of patients achieving HbA1c \7%
remained largely unchanged. A small reduction
in the effect estimate for saxagliptin plus
metformin versus metformin was recorded;
however, this did not change the findings
from the base-case MTC. Patients treated with
alogliptin were still statistically significantly
more likely to achieve HbA1c \7% than those
treated with saxagliptin; however, it should be
noted that the 95% credible interval for
alogliptin plus metformin is very wide [OR
6.39 (3.19–11.85)].
Therefore, the impact of removing studies
with heterogeneity, as identified by the I2
statistic in direct-comparison meta-analyses,
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conclusions drawn from the MTC analysis
comparing HbA1c mean reduction from
baseline and proportion of patients achieving
HbA1c target \7% between DPP-4 inhibitors.
DISCUSSION
Principal Findings
The principal finding of this systematic review
and MTC of the DPP-4 inhibitors is the
demonstration of equivalent effects across the
class in terms of key efficacy and safety outcomes
(HbA1c mean change from baseline, proportion of
patients achieving HbA1c \7%, mean change in
body weight from baseline, and number of
patients with hypoglycemic events between:
alogliptin, linagliptin, saxagliptin, sitagliptin,
and vildagliptin as monotherapy or dual therapy
(plus metformin or SU); alogliptin, linagliptin,
sitagliptin and vildagliptin as dual therapy (plus
pioglitazone); sitagliptin and vildagliptin as dual
therapy (plus insulin); or linagliptin, sitagliptin
and vildagliptin as triple therapy (plus metformin
and SU), in patients with type 2 diabetes whose
glucose levels were insufficiently controlled. The
only treatment comparison for which there was a
statistically significant difference in the treatment
effect was in patients on alogliptin plus
metformin, who achieved HbA1c \7% more
frequently than those treated with saxagliptin
plus metformin [OR 6.41 (95% CI 3.15–11.98)
versus 2.17 (95% CI 1.56–2.95)]; however, it
should be noted that the 95% credible interval
for alogliptin plus metformin is very wide.
In the direct-comparison meta-analyses, the
majority of DPP-4 inhibitors, either as
monotherapy or as dual or triple therapy, were
significantly more effective than the respective
comparator in reducing mean HbA1c (i.e.,
improving glycemic control). The exceptions
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plus SU versus metformin plus SU, and
sitagliptin or vildagliptin plus insulin versus
insulin alone. Although the I2 statistic indicated
moderate to substantial heterogeneity in the
effect estimate and subsequent removal of
outliers resulted in a reduction in the
corresponding I2 statistic, the average effect
sizes and the direction of effect remained
largely unchanged. Therefore, the removal of
studies with heterogeneity had little or no
impact on the overall conclusions drawn from
the MTCs comparing mean change from
baseline in HbA1c and proportion of patients
achieving HbA1c \7% between DPP-4
inhibitors.
The results from the MTC analyses and
direct-comparison meta-analyses of the DPP-4
inhibitors in this paper are in line with
previously published articles by Scheen [2] and
Esposito et al. [5]. Similar to the review of DPP-4
inhibitors by Scheen [2] and the meta-analyses
reported by Esposito et al. [5], the results of the
MTC indicate no differences between the DPP-4
inhibitors, using predefined criteria of
overlapping 95% credible intervals. This was
the case for DPP-4 inhibitors that were used
either as monotherapy or as dual or triple
therapy in combination with other anti-
diabetic treatments (including metformin, SU,
pioglitazone, or insulin). However, the current
analysis expanded on that previously published
by Esposito et al. [5]. In addition to individual
indirect-comparison meta-analyses of DPP-4
inhibitors, we also conducted MTCs of all
DPP-4 inhibitors, including linagliptin
(previously not included by Esposito et al. [5]),
for the same four outcomes.
Separate MTCs were conducted for DPP-4
inhibitors as monotherapy versus placebo or as
dual- or triple-therapy combinations versus the
respective monotherapy or dual-therapy
comparator, as appropriate. Previous analyses
pooled studies of DPP-4 inhibitors versus
placebo and studies of DPP-4 inhibitor
combination therapy versus other anti-diabetic
combinations [5]. Esposito et al. [5] excluded
studies with a randomized duration of
\12 weeks; this current review did not exclude
studies based upon duration (randomized study
durations ranged from 4 weeks to 104 weeks).
Despite these differences, the current study
reached the same conclusion of no difference
between all DPP-4 inhibitors across the four
outcomes analyzed.
Strengths and Weaknesses of the Study
The strength of this analysis is its robust and
transparent design. We conducted a systematic
search and rigorous review of published RCTs of
pharmacologic treatments in patients with type
2 diabetes and inadequate glycemic control,
according to predefined criteria. Further studies,
often unpublished, were identified by reviewing
the reference lists of selected published
systematic reviews and meta-analyses. Data
extracted from included studies of DPP-4
inhibitors were analyzed using robust
statistical methodology. Both direct- and
indirect-comparison data were combined in an
MTC using a Bayesian approach. The Bayesian
approach combines data in a robust and more
intuitive way than a standard frequentist
approach.
The comparison of the DPP-4 inhibitors was
limited to four outcomes (HbA1c mean change
from baseline, proportion of patients achieving
HbA1c \7%, mean change in body weight from
baseline, and number of patients experiencing a
hypoglycemic event).
Studies from which data were extracted were
assessed to establish if they represented a robust
source of information. A potential weakness of
the studies included in the statistical analyses
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was identified: the majority of studies were
deemed to have between one and three
‘unclear’ assessments out of the seven
assessment criteria. If the assessments were
deemed to be ‘unclear’, it was not possible to
differentiate between studies that had been
poorly reported, and studies that were poorly
conducted (i.e., of low quality, making it difficult
to assess the quality/level of bias in the majority of
the studies included in the analysis). Ten studies
eligible for data extraction were deemed to be of
low quality and, therefore, at a high risk of bias.
However, only one of these was eventually
included in the statistical analyses, the
remainder being excluded for other reasons.
Further, owing to the addition of a MESH/
Embase ‘Drug Therapy’ term restriction in the
search string, it is possible that studies not
indexed as drug therapy could have been
overlooked. However, without this search
term, the review would have been
unmanageable in terms of the number of
titles/abstracts to be filtered. Furthermore,
unpublished data were not specifically sought,
despite a structured search strategy to identify
published articles and unpublished studies from
a selection of published systematic reviews and
meta-analyses. It thus remains possible that
some unpublished studies were not identified.
The MTCs were also limited by a number of
factors. In order to have sufficient studies to
allow quantitative analysis, assumptions were
made regarding the imputation of missing
standard errors and to include data for all
DPP-4 inhibitor and comparator doses
reported in all eligible studies identified. In
addition, studies of the various SUs were
pooled. Variability in the efficacy of treatment
doses and/or different SUs is a possible source of
heterogeneity and hence a limitation of the
analyses. Furthermore, small study numbers
remained in some networks, which may have
resulted in uncertain estimated treatment
effects. Extension-phase data were excluded, as
most studies were no longer randomized and
the study population size was generally limited.
Finally, heterogeneity (I2\30%) in the
treatment effect between studies included in the
direct-comparison meta-analyses was also
identified for a number of treatment comparisons.
Although sensitivity analyses were conducted,
where appropriate, to confirm the robustness of
the base-case analyses, heterogeneity in the effect
estimates represents someuncertainty intheoverall
treatment effect.
Conclusion and Further Research
This systematic review and MTC of DPP-4
inhibitors confirmed no difference between
alogliptin, linagliptin, saxagliptin, sitagliptin,
and vildagliptin, either as monotherapy, or as
dual therapy (plus metformin or SU); alogliptin,
linagliptin, sitagliptin, and vildagliptin as dual
therapy (plus pioglitazone); sitagliptin and
vildagliptin as dual therapy (plus insulin), or
linagliptin, sitagliptin, and vildagliptin as triple
therapy (plus metformin and SU). The study
showed that the DPP-4 inhibitors have similar
efficacy in terms of mean reduction (i.e.,
improvement) in HbA1c from baseline, increased
proportion of patients achieving HbA1c \7%,
mean change in body weight from baseline, and
number of patients experiencing a hypoglycemic
event. Further research is required to assess the
long-term safety and efficacy of this class of oral
anti-diabetic agents. The current MTCs excluded
extension-phase data.
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